Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP9 | P14780 | 14/20 | 0.64 |
| ▸ | MMP2 | P08253 | 4/20 | 0.64 |
| ▸ | MMP13 | P45452 | 11/20 | 0.47 |
| ▸ | MMP1 | P03956 | 8/20 | 0.47 |
| ▸ | ADAM17 | P78536 | 6/20 | 0.47 |
| ▸ | MMP8 | P22894 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13639193 | 1.00 | MMP9 (0.64) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13639217 | 0.89 | MMP9 (0.65) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13639252 | 0.89 | MMP9 (0.65) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13570444 | 0.88 | MMP9 (0.78) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13570710 | 0.88 | MMP9 (0.78) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13570445 | 0.88 | MMP9 (0.78) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13639280 | 0.88 | MMP9 (0.64) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13639258 | 0.88 | MMP9 (0.64) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13639262 | 0.88 | MMP9 (0.80) | MMP9MMP2MMP13MMP1ADAM17 | |
| SCHEMBL13639253 | 0.88 | MMP9 (0.80) | MMP9MMP2MMP13MMP1ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2012-11-08 | — | — | US | disclosed |
| EP-2520573-A1 | Compounds with matrix-metalloproteinase inhibitory activity | Westfälische Wilhelms-Universität Münster (DE) | 2012-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282180-A1 | Compounds with Matrix-Metalloproteinase Inhibitory Activity and Imaging Agents Thereof | MMP1, MMP17, MMP25 | MMP9 4/4885MMP2 16/4885MMP13 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.